SML2769
ASS234
≥98% (HPLC)
别名:
N,1-Dimethyl-5-[3-[1-(phenylmethyl)-4-piperidinyl]propoxy]-N-2-propyn-1-yl-1H-indole-2-methanamine, N-[[5-[3-(1-Benzylpiperidin-4-yl)propoxy]-1-methyl-1H-indol-2-yl]methyl]-N-methyl-2-propyn-1-amine
产品名称
ASS234, ≥98% (HPLC)
InChI key
ADCBAOTWERXLAP-UHFFFAOYSA-N
SMILES string
CN1C(CN(CC#C)C)=CC2=C1C=CC(OCCCC(CC3)CCN3CC4=CC=CC=C4)=C2
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
ASS234 is a brain-penetrant and orally active multi-target small molecule (MTSM) against (acetyl & butyryl) cholinesterases (hAChE/hBuChE IC50 = 0.81/1.82 μM), monoamine oxidases (hMAO-A/B IC50 = 0.27/120 nM), histamine H3 receptor (hH3R Ki = 84.2 nM; hH4R Ki >10 μM) and sigma-1/2 receptors (hS1R/rS2R = 2.82/50.3 nM). ASS234 exhibits antioxidative and neuroprotective effects in SH-SY5Y cultures (5 μM) and demonstrates therapeutic efficacy in neurodegerative disease models in vivo via sc. (0.62 mg/kg/d mice; 5 mg/kg rats), ip. (1 mg/kg mice) or po. (1 & 10 mg/kg mice).
Orally active, brain-penetrant, multi-target ligand against MAO-A/B, cholinesterases, H3 & sigma receptors with neuroprotective and pro-cognitive efficacy in vivo.
存储类别
11 - Combustible Solids
wgk
WGK 3
法规信息
新产品
此项目有
Upregulation of Antioxidant Enzymes by ASS234, a Multitarget Directed Propargylamine for Alzheimer's Disease Therapy.
Eva Ramos et al.
CNS neuroscience & therapeutics, 22(9), 799-802 (2016-07-07)
Óscar M Bautista-Aguilera et al.
Journal of medicinal chemistry, 61(15), 6937-6943 (2018-07-04)
Contilisant, a permeable, antioxidant, and neuroprotectant agent, showing high nM affinity at H3R and excellent inhibition of the monoamine oxidases and cholinesterases, is an affine and selective S1R agonist in the nanomolar range, based on the binding affinity and functional
Eva Ramos et al.
Chemical research in toxicology, 31(9), 839-842 (2018-08-23)
ASS234 is a new multitarget molecule with multiple neuroprotective actions that significantly elevate mRNA levels of NRF2 and HSF1 transcriptional factors and of HSP105, HSP90AB1, HSPA1A, HSPA1B, HSPA5, HSPA8, HSPA9, HSP60, DNAJA1, DNAJB1, DNAJB6, DNAJC3, DNAJC5, DNAJC6, HSPB1, HSPB2, HSPB5
Anna Stasiak et al.
Current pharmaceutical design, 20(2), 161-171 (2013-05-25)
Neurodegenerative disorders are associated with different neurochemical and morphological alterations in the brain leading to cognitive and behavioural impairments. New therapeutic strategies comprise multifunctional drugs. The aim of the presented studies is to evaluate in vivo the novel compounds -
Wnt signaling pathway, a potential target for Alzheimer's disease treatment, is activated by a novel multitarget compound ASS234.
Javier del Pino et al.
CNS neuroscience & therapeutics, 20(6), 568-570 (2014-04-10)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持